MorphoSys Targets 2020 Tafasitamab Launch Following Good DLBCL Data
Morphosys says good L-MIND Phase II data back its plan to submit a US BLA to the US Food and Drug Administration by year-end, for a potential mid-2020 approval of tafasitamab.
You may also be interested in...
MorphoSys has chosen Incyte as its global partner for commercializing and further developing its lead asset, the Fc-engineered antibody tafasitamab that targets CD19.
Analysts tip Munich-based company for greatness, but it will need a big pharma partner to take on Roche's Polivy in competitive hemato-oncology market.
Vivoryon CEO explains how QPCTL-targeting small molecule technology will be tested for combination with MorphoSys’s tafasitamab to enhance cancer-killing efficacy.